Greater ciprofloxacin tolerance as a possible selectable phenotype underlying the pandemic spread of the H30 subclone of Escherichia coli sequence type 131

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 11, 2015, Pages 7132-7135

  Johnson, James R ^a,b   Porter, Stephen B ^a   Thuras, Paul ^a,b   Johnson, Timothy J ^b   Price, Lance B ^c   Tchesnokova, Veronika ^d   Sokurenko, Evgeni V ^d  

^a VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; ORGANIC SOLVENT; PORIN; PROTEIN PARC; PROTEIN PARE; ANTIINFECTIVE AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); ESCHERICHIA COLI PROTEIN; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; DRUG TOLERANCE; ESCHERICHIA COLI; ESCHERICHIA COLI SEQUENCE TYPE 131; GENE MUTATION; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR CLONING; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; PROTEIN EXPRESSION; DRUG EFFECTS; ESCHERICHIA COLI INFECTION; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MUTATION;

ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; DNA GYRASE; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; MUTATION;

EID: 84946212969     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01687-15     Document Type: Article

References (25)

1. Manges AR, Tabor H, Tellis P., Vincent C, Tellier P-P. 2008. Endemic and epidemic lineages of Escherichia coli that cause urinary tract infections. Emerg Infect Dis 14:1575-1583. http://dx.doi.org/10.3201/eid1410.080102.
2. Nicolas-Chanoine M., Bertrand X, Madec J-Y. 2014. Escherichia coli ST131, an intriguing clonal group. Clin Microbiol Rev 27:543-574. http://dx.doi.org/10.1128/CMR.00125-13.
3. Johnson JR, Tchesnokova V, Johnston B., Clabots C, Roberts PL, Billig M, Riddel K., Rogers P, Qin X, Butler-Wu S, Price L.B., Aziz M., Nicolas-Chanoine M, Debroy C, Robicsek A., Hansen G, Urban C, Platell JL, Trott DJ, Zhanel G, Weissman SJ, Cookson B, Fang F, Limaye AP, Scholes D, Chattopadhyay S, Hooper DC, Sokurenko E. 2013. Abrupt emergence of a single dominant multi-drug-resistant strain of Escherichia coli. J Infect Dis 207:919-928. http://dx.doi.org/10.1093/infdis/jis933.
4. Petty NK, Ben Zakour N, Stanton-Cook M, Skippington E., Totsika M, Forde B, Phan M-D, Moriela DG, Peters K, Davies M., Rogers BA, Dougand G, Rodriguez-Baño J, Pascual A, Pitout J, Upton M, Paterson DL, Walsh TR, Schembri MA, Beatson SA. 2014. Global dissemination of a multidrug resistant Escherichia coli clone. Proc Natl Acad Sci USA 111:5694-5699. http://dx.doi.org/10.1073/pnas.1322678111.
5. Williamson DA, Roberts SA, Paterson D.L., Sidjabat H., Silvey A, Masters J, Rice M., Freeman JT. 2012. Escherichia coli bloodstream infection after transrectal ultrasound-guided prostate biopsy: implications of fluoroquinolone-resistant sequence type 131 as a major causative pathogen. Clin Infect Dis 54:1406-1412. http://dx.doi.org/10.1093/cid/cis194.
6. Colpan A, Johnston B, Porter S., Clabots C, Anway R, Thao L., Kuskowski MA, Tchesnokova V, Sokurenko EV, Johnson J.R., VICTORY (Veterans Influence of Clonal Types on Resistance: Year 2011) Investigators. 2013. Escherichia coli sequence type 131 (ST131) as an emergent multidrug-resistant pathogen among U.S. veterans. Clin Infect Dis 57: 1256-1265. http://dx.doi.org/10.1093/cid/cit503.
7. Johnson JR, Johnston B, Clabots C., Kuskowski MA, Castanheira M. 2010. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin Infect Dis 51:286-294. http://dx.doi.org/10.1086/653932.
8. Johnson JR, Johnston B, Clabots C., Kuskowski MA, Pendyala S, Debroy C, Nowicki B., Rice J. 2010. Escherichia coli sequence type ST131 as an emerging fluoroquinolone-resistant uropathogen among renal transplant recipients. Antimicrob Agents Chemother 54:546-550. http://dx.doi.org/10.1128/AAC.01089-09.
9. Banerjee R, Johnston B, Lohse C., Porter SB, Clabots C, Johnson JR. 2013. Escherichia coli sequence type ST131 is a dominant, antimicrobial-resistant clonal group associated with healthcare and elderly hosts. Infect Control Hosp Epidemiol 34:361-369. http://dx.doi.org/10.1086/669865.
10. Johnson JR, Johnston B, Kuskowski M.A., Sokurenko EV, Tchesnokova V. 2015. Intensity and mechanisms of fluoroquinolone resistance within the H30 and H30Rx subclones of Escherichia coli sequence type 131 versus other fluoroquinolone-resistant E. coli. Antimicrob Agents Chemother 59:4471-4480. http://dx.doi.org/10.1128/AAC.00673-15.
11. Price LB, Johnson JR, Aziz M, Clabots C., Johnston B, Tchesnokova V, Nordstrom L., Billig M, Chattopadhyay S, Stegger M., Andersen PS, Pearson T, Riddell K, Rogers P., Scholes D, Kahl B, Keim P, Sokurenko EV. 2013. The epidemic of ESBL-producing Escherichia coli ST131 is driven by a single highly virulent subclone, H30-Rx. mBio 6:e00377-13. http://dx.doi.org/10.1128/mBio.00377-13.
12. Johnson JR, Nicolas-Chanoine M, Debroy C., Castanheira M, Robiscek A, Hansen G., Weissman SJ, Urban C, Platell JL, Trott D.J., Zhanel GG, Clabots C, Johnston BD, Kuskowski M.A., the MASTER Investigators. 2012. Comparison of Escherichia coli sequence type ST131 pulsotypes by epidemiologic traits, 1967-2009. Emerg Infect Dis 18:598-607. http://dx.doi.org/10.3201/eid1804.111627.
13. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard - 9th ed. CLSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
14. Swenson JM, Hindler JA, Peterson LR 1995. Special tests for detecting antibacterial resistance, p 1356-1367. In Tenover FC, Jorgensen JH, Sahm DF (ed), Manual of clinical microbiology, 6th ed. ASM Press, Washington, DC.
15. Robicsek A, Strahilevitz J, Jacoby G.A., Macielag M., Abbanat D, Park CH, Bush K, Hooper DC 2006. Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med 12:83-88. http://dx.doi.org/10.1038/nm1347.
16. Morgan-Linnell S.K., Boyd LB, Steffen D, Zechiedrich L. 2009. Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. Antimicrob Agents Chemother 53:235-241. http://dx.doi.org/10.1128/AAC.00665-08.
17. Sorlozano A, Gutierrez J, Jimenez A., de Dios Luna J, Martínez JL. 2007. Contribution of a new mutation inparE to quinolone resistance in extended-spectrum-β-lactamase-producing Escherichia coli isolates. J Clin Microbiol 45:2740-2742. http://dx.doi.org/10.1128/JCM.01093-07.
18. Oethinger M, Kern WV, Goldman J.D., Levy SB. 1998. Association of organic solvent tolerance and fluoroquinolone resistance in clinical isolates of Escherichia coli. J Antimicrob Agents Chemother 41:111-114. http://dx.doi.org/10.1093/jac/41.1.111.
19. Assimacopoulos A, Johnston B, Clabots C., Johnson JR. 2012. Post-prostate biopsy infection with Escherichia coli ST131 leading to epididymo-orchitis and meningitis caused by Gram-negative bacilli. J Clin Microbiol 50:4157-4159. http://dx.doi.org/10.1128/JCM.02026-12.
20. Ender PT, Gajanana D, Johnston B., Clabots C, Tamarkin FJ, Johnson JR 2009. Transmission of extended-spectrum beta-lactamase-producing Escherichia coli (sequence type ST131) between a father and daughter resulting in septic shock and emphysematous pyelonephritis. J Clin Microbiol 47:3780-3782. http://dx.doi.org/10.1128/JCM.01361-09.
21. Schoenknecht FD. 1986. Bacterial tolerance to antimicrobial agents. Clin Microbiol Newslett 8:72-74. http://dx.doi.org/10.1016/0196-4399(86)90016-4.
22. Wolfson JS, Hooper DC, Shih D.J., McHugh GL, Swartz MN. 1989. Isolation and characterization of an Escherichia coli strain exhibiting partial tolerance to quinolones. Antimicrob Agents Chemother 33:705-709. http://dx.doi.org/10.1128/AAC.33.5.705.
23. Wiuff C, Zappala RM, Regoes R.R., Garner KN, Baquero F, Levin BR. 2005. Phenotypic tolerance: antibiotic enrichment of noninherited resistance in bacterial populations. Antimicrob Agents Chemother 49:1483-1494. http://dx.doi.org/10.1128/AAC.49.4.1483-1494.2005.
24. Falla TJ, Chopra I. 1998. Joint tolerance to β-lactam and fluoroquinolone antibiotics in Escherichia coli results from overexpression of hipA. Antimicrob Agents Chemother 42:3282-3284.
25. Theodore A, Lewis K, Vulic M. 2013. Tolerance of Escherichia coli to fluoroquinolone antibiotics depends on specific components of the SOS response pathway. Genetics 195:1265-1276. http://dx.doi.org/10.1534/genetics.113.152306.